A PHASE Ib/II, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-GUÉRIN IN PATIENTS WITH HIGH-RISK NON¿MUSCLEINVASIVE BLADDER CANCER

Awarded By

Contributors

Start/End

  • November 1, 2016 - October 31, 2021